Elaine F Harkness1, Emma Barrow2, Katy Newton2, Kate Green3, Tara Clancy3, Fiona Lalloo3, James Hill2, D Gareth Evans3. 1. Centre for Imaging Sciences, University of Manchester, Manchester, UK. 2. Department of General Surgery, University of Manchester and Central Manchester and Manchester Children's University Hospitals NHS Trust, Manchester, UK. 3. Manchester Centre for Genomic Medicine, St. Mary's Hospital, Manchester, UK.
Abstract
INTRODUCTION: Lynch syndrome is known to cause an increased risk of malignancies, including bowel and endometrial cancers. However, the risk of breast cancer associated with mutations in the mismatch repair (MMR) genes that cause Lynch syndrome is still unclear. MATERIALS AND METHODS: This study assesses the cumulative risk of breast cancer in 106 MLH1 and 118 MSH2 families. Families were referred on the basis of clinical criteria. Pedigree information was obtained, and tumour immunohistochemistry and microsatellite testing performed. Appropriate patients underwent sequencing and multiple ligation dependent probe amplification of all relevant exons of the MMR genes. Kaplan-Meier analysis of cumulative lifetime risk of breast cancer was made combining proven mutation carriers and their first-degree female relatives. RESULTS: After allocation of mutation status, the cumulative risk of breast cancer to 70 years in MLH1 carriers was 18.6% (95% CI 11.3 to 25.9)). This is significantly higher than the cumulative risk for MSH2 which was 11.2% (95% CI 1.4 to 21.0) to age 70 years (p=0.014). The UK population risk is 7.5%-8% at the age of 70 years. Prospective analysis identified six breast cancers in 1120 years of follow-up with an OR of 3.41 (95% CI 1.53 to 7.59). DISCUSSIONS: Female MLH1 carriers would appear to be at moderate risk of breast cancer and should be considered for breast screening at ages earlier than national screening programmes. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
INTRODUCTION:Lynch syndrome is known to cause an increased risk of malignancies, including bowel and endometrial cancers. However, the risk of breast cancer associated with mutations in the mismatch repair (MMR) genes that cause Lynch syndrome is still unclear. MATERIALS AND METHODS: This study assesses the cumulative risk of breast cancer in 106 MLH1 and 118 MSH2 families. Families were referred on the basis of clinical criteria. Pedigree information was obtained, and tumour immunohistochemistry and microsatellite testing performed. Appropriate patients underwent sequencing and multiple ligation dependent probe amplification of all relevant exons of the MMR genes. Kaplan-Meier analysis of cumulative lifetime risk of breast cancer was made combining proven mutation carriers and their first-degree female relatives. RESULTS: After allocation of mutation status, the cumulative risk of breast cancer to 70 years in MLH1 carriers was 18.6% (95% CI 11.3 to 25.9)). This is significantly higher than the cumulative risk for MSH2 which was 11.2% (95% CI 1.4 to 21.0) to age 70 years (p=0.014). The UK population risk is 7.5%-8% at the age of 70 years. Prospective analysis identified six breast cancers in 1120 years of follow-up with an OR of 3.41 (95% CI 1.53 to 7.59). DISCUSSIONS: Female MLH1 carriers would appear to be at moderate risk of breast cancer and should be considered for breast screening at ages earlier than national screening programmes. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Lisa Bush; Melyssa Aronson; Uri Tabori; Brittany B Campbell; Raymond B Bedgood; Kory Jasperson Journal: Fam Cancer Date: 2019-01 Impact factor: 2.375
Authors: Chunling Hu; Steven N Hart; Rohan Gnanaolivu; Hongyan Huang; Kun Y Lee; Jie Na; Chi Gao; Jenna Lilyquist; Siddhartha Yadav; Nicholas J Boddicker; Raed Samara; Josh Klebba; Christine B Ambrosone; Hoda Anton-Culver; Paul Auer; Elisa V Bandera; Leslie Bernstein; Kimberly A Bertrand; Elizabeth S Burnside; Brian D Carter; Heather Eliassen; Susan M Gapstur; Mia Gaudet; Christopher Haiman; James M Hodge; David J Hunter; Eric J Jacobs; Esther M John; Charles Kooperberg; Allison W Kurian; Loic Le Marchand; Sara Lindstroem; Tricia Lindstrom; Huiyan Ma; Susan Neuhausen; Polly A Newcomb; Katie M O'Brien; Janet E Olson; Irene M Ong; Tuya Pal; Julie R Palmer; Alpa V Patel; Sonya Reid; Lynn Rosenberg; Dale P Sandler; Christopher Scott; Rulla Tamimi; Jack A Taylor; Amy Trentham-Dietz; Celine M Vachon; Clarice Weinberg; Song Yao; Argyrios Ziogas; Jeffrey N Weitzel; David E Goldgar; Susan M Domchek; Katherine L Nathanson; Peter Kraft; Eric C Polley; Fergus J Couch Journal: N Engl J Med Date: 2021-01-20 Impact factor: 91.245
Authors: Kristen S Purrington; Ann G Schwartz; Julie J Ruterbusch; Mark A Manning; Mrudula Nair; Angela S Wenzlaff; Stephanie S Pandolfi; Michael S Simon; Jennifer Beebe-Dimmer Journal: Cancer Date: 2020-08-04 Impact factor: 6.860
Authors: Kristen S Purrington; Sreejata Raychaudhuri; Michael S Simon; Julie Clark; Valerie Ratliff; Gregory Dyson; Douglas B Craig; Julie L Boerner; Jennifer L Beebe-Dimmer; Ann G Schwartz Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-08-31 Impact factor: 4.254
Authors: Megan Sheehan; Brandie Heald; Courtney Yanda; Erinn Downs Kelly; Stephen Grobmyer; Charis Eng; Matthew Kalady; Holly Pederson Journal: Eur J Breast Health Date: 2020-04-01